Polypill

A polypill containing a beta-blocker, a mineralocorticoid antagonist, and an SGLT2 inhibitor produced a substantial improvement in compliance to guideline-directed medical therapy for heart failure along with measurable improvements in heart failure control, according to data from a randomized trial [the POLY-HF trial]. Compared with usual care, the polypill was associated with increases in adherence and left ventricular ejection fraction (LVEF) as well as a reduction in hospitalizations over a 6-month period […] [The interviewed physicians] pointed out that most studies show less than half of heart failure patients on optimized doses of all guideline-directed medical therapy. It is not clear that a polypill is the only or best answer to this chronic problem, but Prabhakaran said POLY-HF supports the polypill as “an attractive option.” “These are particularly encouraging results while we wait for hard endpoint trials,” he said.